Abstract: Described herein are HSP-90 inhibitors conjugated to lipids, compositions comprising the conjugates, and methods of use thereof for treating cancer.

Abstract: The current invention describes a conjugate of a targeting moiety linked to a drug via a molecule having high affinity for the targeting moiety at physiological pH such that the drug releases at low pH from the targeting moiety.

Abstract: The present invention relates to formulations and their use to treat ocular disorders such as uveitis. Particularly, the invention relates to a formulation comprising mycophenolic acid (MPA) or a pharmaceutically acceptable salt or derivative thereof; and at least one component selected from the group consisting of preservative, chelating agent, buffering agent, pH modifier, thickening agent, viscosity enhancer or viscosity modifier, antioxidant, tonicity modifier, surfactant, humectant, solvent or co-solvent, emulsifier, co-emulsifier, ointment base, targeting agent, polymer, wetting agent, lubricating agent, suspending agent, and therapeutic agent. The disclosure further provides preparation method of said ophthalmic formulations, a pharmaceutical kit comprising said formulations, and method for treating ocular diseases by administering said formulations.

Abstract: The disclosure provides a process of designing and optimizing supramolecular therapeutics. The disclosure also provides a method for designing and optimizing antibody drug conjugates.

Abstract: The present disclosure relates generally to novel molecules, compositions, and formulations for treatment of bacterial infections in general and more specifically to bacterial infections with antibiotic resistant pathogens.

Abstract: A domain-specific question answering system receives an end-user's question, identifies relevant information from domain-specific documents, composes a natural-language based response including the relevant information to be provided to the end-user. A knowledge base includes a domain-specific ontology and is built from data structures configured to preserve the hierarchy of the informational elements within the domain-specific documents. The question received from the end-user is analyzed to extract the features and the key phrases which are used to identify the relevant data structures. A pre-trained model that is further trained on domain-specific data is used to identify the sentences that include information responsive to the question. A response to the end-user's question is composed from the sentences. The question answering system also enables validation of the answers provided to the users' questions.

Abstract: The present disclosure relates to methods of managing cancer by modulating/inhibiting cap methyltransferase enzyme. The modulation/inhibition is carried out by pharmacological or biological inhibitors, including but not limited to compounds of formula (VIII) or Compound A or A-1. Thus, the present disclosure relates to such inhibitors including compounds of formula (VIII) and their use for management of cancer. In some aspects, the compound of formula (VIII) is Compound 1. The present disclosure also relates to methods of activating B cells or T cells via modulation of cap methyltransferases. The present disclosure also relates to methods of managing cancer with a molecule or biologic that generates unmethylated RNA. The generation of unmethylated RNA activates B cells and presents the RNA to B-cell receptor (BCR). The present disclosure therefore also relates to management of cancer by activating B cells and then adoptively transferring the B cells to exert an anticancer effect.

Abstract: The present disclosure provides methods for treating cancer in amount of a compound of formula (VIII), or a pharmaceutically acceptable salt thereof, wherein Q, linker, and lipid are defined herein, and (ii) a therapeutically effective amount of an immune checkpoint inhibitor. Q-linker-lipid (VIII) In some embodiments, the compound is the following structure (IO-125), or a pharmaceutically acceptable salt thereof; Pharmaceutical compositions comprising a compound of formula (VIII), such as IO-125, or a pharmaceutically acceptable salt thereof, an immune checkpoint inhibitor, and a pharmaceutically acceptable excipient are also described.

Abstract: A domain-specific question answering system receives an end-user's question, identifies relevant information from domain-specific documents, composes a natural-language based response including the relevant information to be provided to the end-user. A knowledge base includes a domain-specific ontology and is built from data structures configured to preserve the hierarchy of the informational elements within the domain-specific documents. The question received from the end-user is analyzed to extract the features and the key phrases which are used to identify the relevant data structures. A pre-trained model that is further trained on domain-specific data is used to identify the sentences that include information responsive to the question. A response to the end-user's question is composed from the sentences. The question answering system also enables validation of the answers provided to the users' questions.

Abstract: A virtual cognitive agent (VCA) system comprises social media communication channels integrated with machine cognition engines. The VCA system connects to an external message platform and accesses posted messages. An intent is determined and sentiment analysis is performed on text elements from the intercepted messages to determine handling of the message. The integrated machine cognition engines determine a response to the captured message. The VCA system may access a corpus or exchange data with the originator of the post or another entity to determine the response. The integrated social media communication channels may connect to an external query response platform and communicate the response to the query response platform.

Abstract: The present disclosure relates generally to novel molecules, compositions, and formulations for treatment of bacterial infections in general and more specifically to bacterial infections with antibiotic resistant pathogens.

Abstract: Described herein is a reporter material platform that can be used to directly monitor the drug response in real-time. The reporter material can include an activator element which undergoes a chemical change in response to an immunonological response to a drug, and the chemical change can be detected using a reporter element. The reporter material can include a drug and a reporter element that are physically constrained in a close proximity. The reporter element produces a signal only when the drug induces a direct or indirect physiological change in the tumor or surrounding tissue. The reporter material platform can self-assemble via supramolecular interactions. This reporter material platform can be used to directly monitor the drug response in real-time.

Abstract: The present disclosure is in relation to the field of nanotechnology and cancer therapeutics. In particular, the present disclosure relates to platinum based compounds comprising platinum moiety, linker moiety and lipid moiety and corresponding nanoparticles thereof. The disclosure further relates to synthesis of said platinum based compounds, nanoparticles and compositions comprising said platinum based compounds/nanoparticles. The disclosure also relates to methods of managing cancer by employing aforesaid carbene compounds, platinum based compounds, nanoparticles and compositions thereof.

Abstract: The compositions and methods described herein relate to the treatment of cancer, e.g. by reducing the regression of cancer cells from regressing into cancer stem cell-like phenotypes and/or reducing the development of drug-resistant cancer cells. In some embodiments, the compositions and methods relate to inhibitors of PI3K pathway kinases and Src family kinases.

Abstract: The present disclosure relates generally to Cellular Signalling inhibitors of compound of Formula I, compositions and formulations comprising the same, methods, processes, and uses thereof. In particular, the present disclosure provides CSF-1R inhibitors demonstrating sustained inhibition of CSF/CSF1R signalling pathway with decreased toxicity. The present disclosure also provides supramolecular combinatorial therapeutics, wherein a CSF-1R inhibitor is combined with one or more of a chemotherapeutic agent, a kinase inhibitor, and an immunoregulator, each of which is optionally conjugated with a lipid. The present disclosure also provides a method for treating cancer, allergy, Systemic lupus erythematosus, nephritis, Chronic Obstructive Pulmonary Disease, and abnormal macrophage functions or any combinations thereof.

Abstract: The present disclosure is in relation to the field of nanotechnology and cancer therapeutics. In particular, the present disclosure relates to platinum based compounds comprising platinum moiety, linker moiety and lipid moiety and corresponding nanoparticles thereof. The disclosure further relates to synthesis of said platinum based compounds, nanoparticles and compositions comprising said platinum based compounds/nanoparticles. The disclosure also relates to methods of managing cancer by employing aforesaid carbene compounds, platinum based compounds, nanoparticles and compositions thereof.

Abstract: The current invention describes a conjugate of a targeting moiety linked to a drug via a molecule having high affinity for the targeting moiety at physiological pH such that the drug releases at low pH from the targeting moiety.

Abstract: The present disclosure relates generally to novel molecules, compositions, and formulations for treatment of bacterial infections in general and more specifically to bacterial infections with antibiotic resistant pathogens.

Abstract: The present disclosure relates generally to novel molecules, compositions, and formulations for treatment of bacterial infections in general and more specifically to bacterial infections with antibiotic resistant pathogens.

Abstract: The current invention discloses targeted drug delivery conjugates comprising a targeting moiety linked to a drug via a molecule having an affinity for the targeting moiety. Typically, the conjugate comprises a targeting ligand and a molecule of interest, e.g., a therapeutic agent. The targeting ligand and the molecule of interest are linked to each other via an affinity ligand. The affinity ligand is further covalently or non-covalently linked to a drug or therapeutic agent. The drug can be modified to make it more soluble and so that it cleaves from the linking molecule at the target site.